Physician profile
Robert Betzu
NPI 1669434163
$896.25
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $772 · 2020: $23.84 · 2021: $7.07 · 2022: $93.21.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $576.61 | 2019 | |
| Abbott Laboratories | $155.56 | 2019-2022 | |
| Kestra Medical Technology Services, INC. | $57.63 | 2022 | |
| Biotronik INC. | $46.69 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36.58 | 2019-2020 | |
| Pfizer INC. | $13.31 | 2022 | |
| Elutia, INC. | $9.87 | 2021-2022 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Betzu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.